Engler R L
Research Service, Veterans Affairs Medical Center, San Diego, CA 92161.
J Card Surg. 1994 May;9(3 Suppl):482-92. doi: 10.1111/jocs.1994.9.3s.482.
Although the effects of adenosine on the heart, including the clinical suppression of cardiac arrhythmias, have been recognized for more than half a century, it is only in the last decade that the therapeutic potential of adenosine has been recognized. Research related to the clinical application of adenosine has concentrated on two areas. The first came directly from early observations about the use of adenosine in treating cardiac arrhythmias, in particular supraventricular tachycardias. The second relates to the use of adenosine to protect the heart from the deleterious consequences of myocardial ischemia and reperfusion. This review will focus on the latter cardioprotective properties of adenosine, particularly those shown by a novel group of drugs termed adenosine regulating agents, the prototype of which is acadesine (Protara).
尽管半个多世纪以来人们已经认识到腺苷对心脏的作用,包括在临床上对心律失常的抑制作用,但直到最近十年,腺苷的治疗潜力才得到认可。与腺苷临床应用相关的研究集中在两个领域。第一个领域直接源于早期关于腺苷用于治疗心律失常,特别是室上性心动过速的观察。第二个领域涉及使用腺苷保护心脏免受心肌缺血和再灌注的有害影响。本综述将聚焦于腺苷的后一种心脏保护特性,特别是一类称为腺苷调节剂的新型药物所表现出的特性,其原型是阿卡地辛(普罗塔拉)。